How to buy Teva Pharmaceutical Industries shares

Own Teva Pharmaceutical Industries shares in just a few minutes.

Posted

Fact checked

Teva Pharmaceutical Industries Limited is a drug manufacturers-specialty & generic business based in the US. Teva Pharmaceutical Industries shares (TEVA.US) are listed on the NYSE and all prices are listed in US Dollars. Teva Pharmaceutical Industries employs 40,039 staff and has a trailing 12-month revenue of around $16.7 billion.

How to buy shares in Teva Pharmaceutical Industries

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: TEVA in this case.
  5. Research Teva Pharmaceutical Industries shares. The platform should provide the latest information available.
  6. Buy your Teva Pharmaceutical Industries shares. It's that simple.
The whole process can take as little as 15 minutes.

Teva Pharmaceutical Industries share price

Use our graph to track the performance of TEVA stocks over time.

Teva Pharmaceutical Industries shares at a glance

Information last updated 2021-01-23.
Latest market close$N/A
52-week range$6.25 - $13.56
50-day moving average $10.7079
200-day moving average $10.1964
Wall St. target price$11.82
PE ratio 872
Dividend yield N/A (0%)
Earnings per share (TTM) $0.004
Promoted
eToro Free Stocks

Invest in Teva Pharmaceutical Industries shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Your first 100 trades are free with Fineco, T&Cs apply.
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
Stake
£0
£0
Zero platform fee
Join and receive a free share worth up to £100
Access unlimited commission-free trading on 3,800+ US stocks and ETFs with Stake. Capital at risk.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Degiro Share Dealing
£1.75 + 0.022% (max £5.00)
£1.75 + 0.022% (max £5.00)
Portfolio transfer fees (in & out)
Degiro is widely seen as one of the best low-cost share brokers, for people who are looking to trade regularly. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Open an ISA, Trading Account or SIPP you will get £100 of free trades to buy or sell any investment (new customers only).
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Moneyfarm helps you meet your investment goals with fully-managed portfolios designed around you. Capital at risk.
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Legal & General stocks and shares ISA
Legal & General stocks and shares ISA
£100 or £20 a month
0.61%
N/A
Legal & General is a big financial services company which offers insurance, lifetime mortgage, pensions and stocks and shares ISAs. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
Penfold
Penfold
No minimum
4 portfolios
0.75-0.88%
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Teva Pharmaceutical Industries stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Teva Pharmaceutical Industries under- or over-valued?

Valuing Teva Pharmaceutical Industries stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Teva Pharmaceutical Industries's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Teva Pharmaceutical Industries's P/E ratio

Teva Pharmaceutical Industries's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 872x. In other words, Teva Pharmaceutical Industries shares trade at around 872x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Teva Pharmaceutical Industries's PEG ratio

Teva Pharmaceutical Industries's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9526. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Teva Pharmaceutical Industries's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Teva Pharmaceutical Industries's EBITDA

Teva Pharmaceutical Industries's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $4.6 billion.

The EBITDA is a measure of a Teva Pharmaceutical Industries's overall financial performance and is widely used to measure a its profitability.

Teva Pharmaceutical Industries financials

Revenue TTM $16.7 billion
Operating margin TTM 18.19%
Gross profit TTM $7.5 billion
Return on assets TTM 3.54%
Return on equity TTM -32.82%
Profit margin -24.18%
Book value $8.753
Market capitalisation $13.1 billion

TTM: trailing 12 months

How to short and sell Teva Pharmaceutical Industries shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "TEVA.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 33.9 million Teva Pharmaceutical Industries shares held short by investors – that's known as Teva Pharmaceutical Industries's "short interest". This figure is 3.1% up from 32.9 million last month.

There are a few different ways that this level of interest in shorting Teva Pharmaceutical Industries shares can be evaluated.

Teva Pharmaceutical Industries's "short interest ratio" (SIR)

Teva Pharmaceutical Industries's "short interest ratio" (SIR) is the quantity of Teva Pharmaceutical Industries shares currently shorted divided by the average quantity of Teva Pharmaceutical Industries shares traded daily (recently around 7.6 million). Teva Pharmaceutical Industries's SIR currently stands at 4.45. In other words for every 100,000 Teva Pharmaceutical Industries shares traded daily on the market, roughly 4450 shares are currently held short.

However Teva Pharmaceutical Industries's short interest can also be evaluated against the total number of Teva Pharmaceutical Industries shares. In this case Teva Pharmaceutical Industries's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Teva Pharmaceutical Industries shares in existence, roughly 30 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Teva Pharmaceutical Industries.

Find out more about how you can short Teva Pharmaceutical Industries stock.

Teva Pharmaceutical Industries's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Teva Pharmaceutical Industries.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Teva Pharmaceutical Industries's total ESG risk score

Total ESG risk: 58.8

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Teva Pharmaceutical Industries's overall score of 58.8 (as at 01/01/2019) is pretty weak – landing it in it in the 76th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Teva Pharmaceutical Industries is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Teva Pharmaceutical Industries's environmental score

Environmental score: 77.02/100

Teva Pharmaceutical Industries's environmental score of 77.02 puts it squarely in the 87th percentile of companies rated in the same sector. This could suggest that Teva Pharmaceutical Industries is a laggard in its sector in terms of its environmental impact, and exposed to a greater level of risk.

Teva Pharmaceutical Industries's social score

Social score: 47.2/100

Teva Pharmaceutical Industries's social score of 47.2 puts it squarely in the 58th percentile of companies rated in the same sector. This could suggest that Teva Pharmaceutical Industries is pretty average in terms of looking after its workforce and social impact.

Teva Pharmaceutical Industries's governance score

Governance score: 65.26/100

Teva Pharmaceutical Industries's governance score puts it squarely in the 81st percentile of companies rated in the same sector. That could suggest that Teva Pharmaceutical Industries is a laggard in its sector in terms of responsible leadership, and exposed to a greater level of risk.

Teva Pharmaceutical Industries's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Teva Pharmaceutical Industries scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Teva Pharmaceutical Industries hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Teva Pharmaceutical Industries Limited was last rated for ESG on: 2019-01-01.

Total ESG score 58.8
Total ESG percentile 76.26
Environmental score 77.02
Environmental score percentile 87.16
Social score 47.2
Social score percentile 58.24
Governance score 65.26
Governance score percentile 80.64
Level of controversy 3

Teva Pharmaceutical Industries share dividends

We're not expecting Teva Pharmaceutical Industries to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have Teva Pharmaceutical Industries's shares ever split?

Teva Pharmaceutical Industries's shares were split on a 2:1 basis on 1 July 2004. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Teva Pharmaceutical Industries shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Teva Pharmaceutical Industries shares which in turn could have impacted Teva Pharmaceutical Industries's share price.

Teva Pharmaceutical Industries share price volatility

Over the last 12 months, Teva Pharmaceutical Industries's shares have ranged in value from as little as $6.25 up to $13.56. A popular way to gauge a stock's volatility is its "beta".

TEVA.US volatility(beta: 1.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Teva Pharmaceutical Industries's is 1.4958. This would suggest that Teva Pharmaceutical Industries's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Teva Pharmaceutical Industries overview

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

Frequently asked questions

More guides on Finder

  • How to buy Teva Pharmaceutical Industries shares

    Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Charlie’s Holdings shares

    Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Lemonade shares

    Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Unity Software shares

    Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor

  • How to buy FuelCell Energy shares

    Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.

  • How to buy Teva Pharmaceutical Industries shares

    Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor

  • How to buy Zomedica Pharmaceuticals shares

    Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.

  • How to buy YRC Worldwide shares

    Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.

  • How to buy Xeros Technology Group shares

    Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.

  • How to buy Xpediator shares

    Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site